PRODIGIOSANUM (Prodigiosanum) — the high-molecular lipopolisakharidny complex of a bacterial origin which is a stimulator of nonspecific resistance of an organism.
PRODIGIOSANUM is received in 1961 E. Weisberg and 3. V. Ermolyeva by the modified Webster's method (M. Webster) from Serratia marcescens (the old name Bacterium prodigiosum).
PRODIGIOSANUM — amorphous powder or inodorous porous weight and taste. It is almost insoluble in organic solvents, we will dissolve in divorced acids and alkalis; it is hygroscopic; in water or isotonic solution of sodium chloride forms opalescent solutions.
PRODIGIOSANUM activates factors immuno-biol. reactivity, causing two-phase reaction: during the first hours — a nek-swarm oppression of indicators immunobiol. reactivity, a leukopenia, and then (of 24 — 48 hours to 4 — 7 days) — leukocytosis, considerable stimulation of phagocytosis, cellular metabolism and processes of cooperation of immunocompetent cells, increase in level of a lysozyme, interferon, immunoglobulins, bactericidal activity of blood serum.
PRODIGIOSANUM increases efficiency of antibacterial therapy, promotes a rassasyvaniye of the inflammatory centers, accelerates processes of reparative regeneration, improves portability of antineoplastic cytostatic and radiation therapy. Items apply as additional nonspecific excitant in complex treatment of the diseases which are followed by oppression immunobiol. reactivity and for prevention of their recurrence in therapeutic, otorhinolaryngological, surgical, oncological, dermatological, dental, gynecologic and ftiziatrichesky practice (generally at chronic, inertly current processes).
In ginekol. to practice PRODIGIOSANUM is applied as nonspecific excitant at hron, recurrent inflammatory diseases of a uterus, its appendages, a pelvic peritoneum and cellulose, and also at cicatricial and commissural processes of genitalias with the expressed pain syndrome caused by neuralgia of pelvic nerves. For the purpose of the prevention of an exacerbation of chronic respiratory diseases of P. use independently or in combination with other drugs. Use of Prodigiosanum in the accruing doses is the most rational: intramusculary from 15 to 75 mkg of 1 times in 4 — 5 days (4 — 5 introductions on a course of treatment). P.'s treatment determination of content in blood of S-reactive protein to treatment, in 1 — 2 days after the second injection of P. and upon termination of a course carry out under control a wedge, blood test.
Treatment by PRODIGIOSANUM is performed in a complex, against the background of treatment by antibiotics or other causal and pathogenetic treatment. In ginekol. to practice after the second injection appoint physical therapy (decimeter waves, magnetic field, an electrophoresis of medicines). After a course of treatment of P. at gynecologic, LOR-diseases, and also at an allergic pruritic dermatosis at children the additional climatotherapy or a resort therapy, physical therapy, the fortifying and tempering actions is recommended for fixing of effect. It is reasonable to appoint repeated courses of treatment PRODIGIOSANUM not earlier than in 6 — 8 weeks, for prevention of a recurrence — 1 — 2 time a year.
After P.'s introduction the general, focal and local reactions, frequency of emergence and which degree depend on individual sensitivity of patients are possible. The general reaction (fervescence to 37,5 — 38,2 °, a headache, an ache in joints) arises in 2 — 4 hours and continues till 8 — 16 o'clock. Focal reaction is shown as an aggravation of the basic or the accompanying inflammatory processes. The hyperemia and morbidity in an injection site is possible.
Contraindication for P.'s use cardiovascular diseases in a stage of subcompensation and a decompensation are; sharply and subacutely current inflammatory processes of genitalias, purulent tubo-ovarian educations (e.g., pyosalpinx); active form of tuberculosis; organic lesions of c. and. page, especially with disturbances of thermal control, epilepsy. Items apply with care at the expressed allergic conditions and disturbances of cerebral circulation.
Drug release in the form of 0,005% of solution for intramuscular injections in ampoules.
Bibliography: Antibiotics, bacterial polysaccharides, interferon, under the editorship of 3. V. Ermolyeva, page 255, M., 1968; E r-molyeva 3. Century and Weisberg G. E. Stimulation of nonspecific resistance of an organism and bacterial polysaccharides, M., 1976; Kuzmin V. G., K. M. Mullet and M e d in e d e in and M. M. O the stimulating influence of Prodigiosanum on nonspecific reactivity at a typroid, dysenteric and staphylococcal infection, Antibiotics, t. 23, No. 3, page 264, 1978.; Matveeva E. E. and Gurova V. V. To a question of the organization of stage treatment at gynecologic diseases of inflammatory character, Akush. and ginek., No. 12, page 18, 1974; Matveeva E. E. and Zhukovsky L. N. Experience of use of Prodigiosanum at treatment of chronic inflammatory diseases of female generative organs, in the same place, No. 12, page 30, 1967; Sobolev V. R. and Weisberg G. E. Prodigiosanum as a stimulator of immunobiological reactivity of an organism, Chemical - pharm. zhurn., t. And, No. 3, page 142, 1977; Scherbakova E. G. and d river. Influence of gentamycin in combination with Prodigiosanum on an immune responsiveness of an organism. Antibiotics, t. 24, No. 9, page 679, 1979.
E. G. Scherbakova; E. E. Matveeva (wedge.).